Cancer Research AACR Membership  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gandhi, V.
Right arrow Articles by Rosen, S. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gandhi, V.
Right arrow Articles by Rosen, S. T.
[Cancer Research 61, 5474-5479, July 15, 2001]
© 2001 American Association for Cancer Research


Experimental Therapeutics

8-Chloro-cAMP and 8-Chloro-adenosine Act by the Same Mechanism in Multiple Myeloma Cells1

Varsha Gandhi2, Mary Ayres, Robert G. Halgren, Nancy L. Krett, Robert A. Newman and Steve T. Rosen

Department of Experimental Therapeutics and Leukemia [V. G.] and the Newman Department of Experimental Therapeutics [M. A., R. A. N.], the University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611 [R. G. H., N. L. K., S. T. R.]

Previous work with 8-chloro-cAMP (8-Cl-cAMP) has raised questions as to whether it works as a cAMP analogue or as a nucleoside analogue after its conversion to 8-chloro-adenosine (8-Cl-Ado). Although degradation of 8-Cl-cAMP to 8-Cl-Ado in culture medium or plasma has been shown, cellular pharmacology data are missing. The purpose of the present study was to identify the cellular metabolism of these drugs and their actions in a human multiple myeloma cell line. The cells were incubated with either 8-Cl-Ado or 8-Cl-cAMP to follow the cellular metabolism of these agents. Both 8-Cl-cAMP and 8-Cl-Ado incubation resulted in the accumulation of 8-Cl-Ado mono-, di-, and tri-phosphate (8-Cl-ATP), however, the triphosphate was the major cytotoxic metabolite. Accumulation of 8-Cl-ATP was dependent on both the exogenous concentration of 8-Cl-Ado and incubation time. At the 10 µM level of 8-Cl-Ado, >400 µM 8-Cl-ATP accumulated in multiple myeloma cells after continuous incubation for 12 h. Similar incubation with 8-Cl-cAMP also resulted in accumulation of 8-Cl-ATP in the cells, albeit at a lower level. The formation of 8-Cl-ATP from 8-Cl-cAMP was inhibited by >80% in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine in the medium, suggesting extracellular conversion of 8-Cl-cAMP to 8-Cl-Ado. Cells lacking Ado kinase did not accumulate 8-Cl-ATP, either from 8-Cl-Ado or 8-Cl-cAMP, and were resistant to these agents. There was also a decline in the endogenous level of the cellular ATP pool parallel to the accumulation of 8-C1-ATP. The elimination of 8-Cl-ATP was biphasic and slow from the cells. The accumulation of 8-Cl-ATP and a decline in the ATP pool inhibited RNA synthesis but did not affect DNA synthesis for up to 12 h of incubation. Taken together, these data demonstrate that the cytotoxic metabolite of 8-Cl-Ado and 8-Cl-cAMP is 8-Cl-ATP. Hence, 8-Cl-cAMP serves as a prodrug and is converted to 8-Cl-Ado in medium with subsequent phosphorylation to accumulate as 8-Cl-ATP in cells. At the cellular level, 8-Cl-ATP is associated with a decrease in the endogenous ATP pool; at the nuclear level, it inhibits RNA synthesis.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
A. J. Robinson-White, H.-P. Hsiao, W. W. Leitner, E. Greene, A. Bauer, N. L. Krett, M. Nesterova, and C. A. Stratakis
Protein Kinase A-Independent Inhibition of Proliferation and Induction of Apoptosis in Human Thyroid Cancer Cells by 8-Cl-Adenosine
J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 1020 - 1029.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. Stellrecht, C. J. Phillip, F. Cervantes-Gomez, and V. Gandhi
Multiple Myeloma Cell Killing by Depletion of the MET Receptor Tyrosine Kinase
Cancer Res., October 15, 2007; 67(20): 9913 - 9920.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Balakrishnan, W. G. Wierda, M. J. Keating, and V. Gandhi
Mechanisms of Cell Death of Chronic Lymphocytic Leukemia Lymphocytes by RNA-Directed Agent, 8-NH2-Adenosine
Clin. Cancer Res., September 15, 2005; 11(18): 6745 - 6752.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y.-H. Ahn, J. M. Jung, and S. H. Hong
8-Chloro-Cyclic AMP-Induced Growth Inhibition and Apoptosis Is Mediated by p38 Mitogen-Activated Protein Kinase Activation in HL60 Cells
Cancer Res., June 1, 2005; 65(11): 4896 - 4901.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Balakrishnan, C. M. Stellrecht, D. Genini, M. Ayres, W. G. Wierda, M. J. Keating, L. M. Leoni, and V. Gandhi
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP
Blood, June 1, 2005; 105(11): 4455 - 4462.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. Ghias, C. Ma, V. Gandhi, L. C. Platanias, N. L. Krett, and S. T. Rosen
8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: Role in induction of apoptosis in multiple myeloma
Mol. Cancer Ther., April 1, 2005; 4(4): 569 - 577.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
C. M. Stellrecht, L. S. Chen, and V. Gandhi
Inhibition of Oncogene Expression by RNA-Directed Agents
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 338 - 343.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. L. Krett, K. M. Davies, M. Ayres, C. Ma, C. Nabhan, V. Gandhi, and S. T. Rosen
8-Amino-adenosine is a potential therapeutic agent for multiple myeloma
Mol. Cancer Ther., November 1, 2004; 3(11): 1411 - 1420.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. S. Chen and T. L. Sheppard
Chain Termination and Inhibition of Saccharomyces cerevisiae Poly(A) Polymerase by C-8-modified ATP Analogs
J. Biol. Chem., September 24, 2004; 279(39): 40405 - 40411.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. Stellrecht, C. O. Rodriguez Jr., M. Ayres, and V. Gandhi
RNA-Directed Actions of 8-Chloro-Adenosine in Multiple Myeloma Cells
Cancer Res., November 15, 2003; 63(22): 7968 - 7974.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. C. Anderson and W. S. Dalton
Synopsis of a Research Roundtable Presented on Cell Signaling in Myeloma: Regulation of Growth and Apoptosis--Opportunities for New Drug Discovery
Mol. Cancer Ther., December 1, 2002; 1(14): 1361 - 1365.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.